BRIDGEWATER, NJ--(Marketwire - December 11, 2007) - Alpharma Inc. (NYSE: ALO), a global specialty pharmaceutical company, announced today that the company expects 2008 revenue growth in the range of 13% to 15%, and 2008 diluted earnings per share ("EPS") in the range of $0.30 to $0.50, excluding the EPS impact of potential milestone payments associated with the company's recent licensing agreements. The 2008 outlook is based on the following key assumptions:
